In this context, further studies should be necessary to identify the suboptimal drug exposure related to the cross-resistance to IMI-REL and MER-VAB, characterize specific-mutations related to cross-resistance emerging in vivo under different antimicrobial therapy, and define the optimal antimicrobial treatment for infections due to cross-resistant KPC-Kp. This evidence concerns the gene NPPA and infection.